A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Polymyalgia Rheumatica
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Sirukumab (Primary) ; Prednisone
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 16 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 May 2017 Planned End Date changed from 24 Jan 2021 to 26 Aug 2021.
- 22 May 2017 Planned primary completion date changed from 25 Jan 2020 to 26 Aug 2020.